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ess: m.l.everard@SheffiSummary Levels of exhaled nitric oxide (eNO) are elevated in subjects with
asthma and fall in response to oral or inhaled steroids. This study explored the
possibility the measurement of eNO levels could be used to identify subjects who
were not adhering to their treatment regimen.
Twenty children with asthma attending the respiratory clinic were recruited.
Each attended on four occasions 1 month apart when eNO levels were measured. A
data logger attached to a pressurised metered dose inhaler was used to objectively
monitor use of inhaled corticosteroids (ICSs). The correlation between day and dose
compliance with eNO was assessed.
The data demonstrated a weak but non-significant correlation between eNO and
both day (r ¼ 0.055, P ¼ 0.67) and dose (r ¼ 0.153, P ¼ 0.23). A recorded value of eNO
less than 12 was associated with day compliance rates of 3–97%. Of the 19 recorded
eNO values greater than 12ppb almost 80% were from subjects with a day compliance
of less than 50% during the preceding month. Of the four values greater than 12ppb and
day compliance 460% one subject had a poor inhaler technique, one had a mild viral
exacerbation and one appeared to be associated with increase pollen exposure.
The measurement of eNO may prove to be a useful tool in helping to manage
children with asthma but further work is required to define its precise role. Elevated
eNO levels in asthmatic children taking ICSs are likely to reflect poor compliance but
confounding factors such as disease activity and inhaler technique need to be carefully
considered.
& 2006 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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The introduction of inhaled corticosteroids (ICS) in
the early 1970s transformed the management of
asthmatic patients.1 It has been shown that the use
of ICSs reduces day and night-time symptoms,
reduces exercise induced fall in lung function,
reduces the frequency and severity of exacerba-
tions and has probably had some impact on
mortality.2–6 A systematic review comparing ICS
treatment against placebo in children with asthma
suggested that corticosteroids produce a 50%
reduction in asthma symptoms and 68% reduction
in the need for rescue therapy with oral corticos-
teroids following acute exacerbations compared to
control groups.2 However, in order to obtain these
benefits ICSs must be taken regularly and many
studies have shown that compliance with a treat-
ment regimen amongst asthmatic patients in
routine practice is frequently poor. Poor regimen
compliance (poor adherence) has been shown to
result in increased morbidity7–18 and appears to be
associated with an increased mortality.
Reliably identifying non-compliance may prove to
be very valuable in attempting to understand the
factors contributing to on-going symptoms in
asthmatic patients under medical review. Unfortu-
nately, there is currently no reliable means to
assessing compliance in routine practice. The few
objective studies assessing health-care profes-
sionals assessment of compliance amongst asth-
matic subjects indicated that this is generally no
more accurate than tossing a coin.11,13 Indeed, in
one large study physicians were found to greatly
over estimate compliance and physician assessment
was found to be less reliable than either canister
weighing or patient completed questionnaires,
both of which significantly over-estimated compli-
ance.13 Personal characteristics provide few im-
mediate clues in that compliance with a given
asthma treatment regime does not appear to be
influenced by age, socio-economic status, knowl-
edge of the disease or disease severity. However,
psychological factors, and depression in particular,
are thought to have some correlation with poor
regime compliance.10 Anxiety is associated with
over-reliance on b agonist use and is not associated
with improved adherence to in ICS use.10,14
Personal reporting of compliance is notoriously
unreliable.8–12,16
Over the past few years there have been many
papers indicating that exhaled nitric oxide (eNO)
levels are elevated in untreated asthmatics and
during acute exacerbations and that these fall in
response to treatment with oral or inhaled ster-
oids.18–21 On the basis of these observations it hasmay be a useful and reliable non-invasive means of
diagnosing22 and monitoring airways inflammation
in patients with asthma.24,25 However, others have
questioned its value in monitoring disease activity
in treated patients.26,27 One study did find a
correlation between fall in eNO and compliance,
as measured by counting unused doses in a
Turbohaler, when budesonide was commenced in
children with mild-to-moderate asthma irrespec-
tive of atopic status. However, the authors did not
report any correlation between absolute eNO levels
and compliance.28
Despite the lack of any study using objective
measures of compliance to determine the relation-
ship between compliance and eNO levels it has
been frequently suggested that measurements of
eNO would be of considerable value in monitoring
compliance with treatment regimens.21 The pur-
pose of this study was to obtain objective data
relating to regime compliance amongst asthmatic
children and correlate this with eNO levels. In this
‘real-life study all children with a diagnosis of
asthma based on a clear response to therapy were
eligible for inclusion and no attempt was made to
select on the basis of atopic status or disease
severity.Method
Twenty children aged between 7–14 years of age
with a diagnosis of asthma based on a clear
response to therapy attending asthma clinics at
the Sheffield Children’s Hospital were recruited
over a 12-month period. Local Ethics Committee
approval was obtained for the study. Patients were
on a stable dose of ICSs for at least 3 months prior
to entry into the study. All were reporting
experiencing symptoms at least three times per
week but they had not experienced an exacerba-
tion with the previous 6 weeks. All subjects
entering the study were using pressurised metered
dose inhalers and holding chambers as their
delivery system for ICS as we did not wish to
change delivery systems at entry to the study and
the data loggers were pMDI specific. In this ‘real-
life’ study patients with asthma were included
irrespective of their atopic status. The study was
approved by the South Sheffield Ethics committee
and all subjects and their parents provided written
consent.
Patients attended on four occasions at 1-monthly
intervals. At each visit, eNO measurements were
obtained together with lung function measure-
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Figure 1 (a) Correlation between recorded day compli-
ance and eNO (r ¼ 0.055, P ¼ 0.67). Each patient is
represented by three data points. (b) Correlation
between recorded dose compliance and eNO
(r ¼ 0.153, P ¼ 0.24). Each patient is represented by
three data points.
M. Katsara et al.1514ments and clinical assessment based on reported
symptoms. At visit 1 patients were issued with a
standard pressurised metered dose inhaler contain-
ing their normal ICS. Attached to the inhaler was a
datalogger (Medtrac Technologies, Lakewood,
USA), which recorded time and date of all actua-
tions. Patients were fully informed regarding the
purpose of these monitoring devices.
eNO recordings were made at each visit using a
Logan Sinclair chemiluminescence analyser (Logan
Research, Rochester, UK). eNO levels were re-
corded following the ERS task force recommenda-
tions29 using an expiratory flow of 50ml/s and
measurements taken from the plateau portion of
the curve.30
The correlation between eNO and both day and
dose compliance was assessed. Day compliance
reflects the number of days the advised number of
doses were taken while dose compliance reflects
the number of doses taken as a proportion of the
nominal prescribed doses during that period. A
patient prescribed a twice-daily regimen who only
administered a single dose each day would have a
day compliance of zero but a dose compliance of
50%.
The Spearman correlation coefficient was used to
assess the relationship between the variables as the
data in all the variables of interest was not
normally distributed.Results
Of the children included in the study 13 had clear
evidence of personal atopy with raised IgE, positive
skin prick tests, or on-going atopic dermatitis and/
or ‘hay fever’. Of the remainder four had a very
strong family history with at least one first-degree
relative and three appeared not to be atopic. FEV1
ranged from 73% to 120% at entry to the study.
The relationships between day and dose com-
pliance and measured eNO are shown in Figs. 1a
and 1b. Each point represents data from an
individual visit with three data points per patient.
There was a negative non-significant correlation
between day compliance and eNO (r ¼ 0.055,
P ¼ 0.67). An apparently stronger negative correla-
tion between dose compliance and eNO was
observed but again this was not statistically
significant (r ¼ 0.153, P ¼ 0.24).
A number of patterns emerged from examining
individual patient data as shown in Fig. 1a. Seven
subjects appeared to have satisfactory levels of
compliance (day compliance460%) and eNO levels
below 10. Of these six had a personal evidence ofpersonal atopy with hayfever and or eczema in
addition to asthma and the seventh had a strong
family history of atopy.
Of the three subjects in whom there was no clear
evidence either personal atopy or close family
history of atopy, two subjects had elevated eNO
levels on at least one occasion. Three subjects had
eNO levelso10 ppb at each visit but had evidence
of poor compliance throughout. Two of these had
clear personal evidence of atopy (one elevated IgE
and one with eczema and hayfever) while a fourth
had very variable rates of compliance which was
not reflected in the eNO levels which remained low
throughout.
Nine subjects had persistently or intermittently
raised eNO. Of these, three subjects had poor
regime compliance throughout (day adherence
o40%) with elevated eNO. One subject appeared
to have good day compliance (475% at each visit)
but despite this had an eNo level of 19 ppb at one
visit. In four subjects, day compliance fell following
the first period and this was accompanied by a
marked increase in eNO.
eNO levels of 412 ppb where recorded on 19
occasions. Of these15 were associated with
day compliance during the previous month of less
than 50%. However, four (420%) of these values
were associated with a day compliance of 460%
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influence eNO measurements during clinic visits.
Alternative explanations were apparent in three.
One appeared to be attributable to poor inhaler
technique and in one subject the elevated eNO
appeared to be attributable to a mild viral
exacerbation of asthma. For a third subject the
elevated eNO was associated with increase hay
fever symptoms and presumably reflected in-
creased lower airways inflammation in response to
the allergen or contamination from the upper
airway.Discussion
The data obtained in this study undertaken in
unselected children with a clinical diagnosis of
asthma suggests that the measurement of elevated
levels of eNO may be helpful in identifying patients
with poor regime compliance but caution must be
exercised when interpreting results. When consid-
ering the group as a whole there was weak but non-
significant negative correlation between eNO and
both day and dose compliance. The only other
study that we are aware of exploring this issue
(presented as an abstract31), reported a negative
correlation between eNO and compliance but his
study was based on self-reporting of inhaler use
which is notoriously inaccurate. Although our study
did not demonstrate a statistically significant
correlation, elevated levels were most commonly
associated with poor compliance. However, our
data suggests that a number of possible confound-
ing factors such as poor inhaler technique, mild
viral-induced exacerbations and hay fever may
result in elevated eNO levels independent of the
patient’s compliance.
Our data indicates that poor regimen compliance
is the most likely explanation for elevated eNO
levels in asthmatic patients attending the clinic but
other causes need to be considered. In our study
more than 20% of elevated levels were attributable
to causes other than poor regimen compliance. As
noted above, regime compliance amongst those
with eNO levels in the ‘normal’ range was highly
variable and therefore a ‘normal’ value does not
indicate ‘good’ adherence. . The ‘day compliance’
during the preceding month in those whose eNO
was less than 10 ppb ranged from 3–97%.
A number of factors may have contributed to the
lack of a significant correlation. It is possible that
improved correlation may have been achieved if
more subjects had been included but this would
still not alter the findings that in some subjects,eNO are elevated despite good compliance and in
others low levels are recorded despite poor
compliance. Recognition of the reasons for these
‘outliers’ is important when using eNO measure-
ments in the clinic.
The inclusion of three children without clear
evidence of atopy may have contributed since
there is evidence that eNO levels are more closely
related to atopic asthma. However,this seems
unlikely in that elevated eNO levels were recorded
in two of the three ‘non-atopic’ children, that is
those who did not have a clear personal history of
atopy or strong family history of atopy in first-
degree relatives while two of the three with
persistently poor compliance and low eNO were
atopic. We deliberately did not undertake skin
prick tests or measure total IgE and RASTS in those
who had not already had such investigations. We
wished to undertake a ‘real life’ to explore the
possible application of eNO in a standard clinic. In
the UK, the majority of subjects with asthma would
be managed in primary care and the majority would
not have had skin prick tests or RASTS performed.
In part the poor correlation observed in our study
can be attributed to those low levels of eNO in
subjects with poor compliance. This is unlikely to
be due to the inclusion of non-atopic subjects as
two of the three subjects had unequivocal evidence
of being atopic individuals. A more likely explana-
tion is that these subjects had relatively mild
disease despite reporting significant symptoms.
Alternatively they may represent subjects in whom
adherence improved during the few days prior to
assessment since eNO levels are reported to
respond rapidly to the administration of systemic
or inhaled steroids but the data did not support this
suggestion.
High levels of eNO despite adequate compliance
will also tend to reduce the correlation between
compliance and eNO and contribute to the lack of
significant correlation. When considering patients
with an eNO level above 12 ppb the majority had a
day compliance level below 50% suggesting that
elevated levels do reflect poor compliance. How-
ever, in more than 20% of subjects the elevated
levels of eNO were derived from subjects who
would appear to be an acceptable day compliance
of greater than 60%. Regimen compliance is only
one of a number of factors that may influence a
therapeutic response to ICSs. Even if a patient
adheres with a treatment regimen they may still
have on-going inflammation in the lower airway
with elevated eNO levels if their inhaler technique
is poor and drug is not being delivered to the
lungs.32 Similarly the underlying inflammation may
be increased in the short term due to exacerbations
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or allergen challenges. In two subjects studied
during the summer, hay fever appeared to be a
possible confounding factor contributing to ele-
vated eNO levels. Indeed the highest levels were
recorded in an individual in whom upper rather
than lower airways symptoms were most trouble-
some at the time. However, the technique used to
measure eNO should minimise contamination from
the upper airway and normal levels of eNO were
observed in other subjects with symptomatic hay
fever. It has been proposed that elevated eNO may
also be attributed to being on ‘inadequate dose’34
but this did not appear to be a factor in any of the
children in our study. If patients with a good inhaler
technique were compliant but on an inadequate
dose we would have expected to see persistently
elevated eNO levels despite good compliance but
this pattern was not observed in any of the
subjects.
Our findings that there is a relatively poor
correlation between eNO and therapy are not
unique. A previous study assessing the response to
prednisolone in 23 atopic subjects with severe
asthma found that eNO levels were in the ‘normal
range’ both before and after prednisolone despite
on-going symptoms in more than a quarter of
subjects.34 Similarly eNO remained elevated in
20% of subjects despite apparently complying with
prednisolone therapy monitored by measuring
serum levels. These results combined with our
findings suggest that the relationship between eNO,
treatment and symptoms is more complex than is
often portrayed and further work is required to
clarify the role of eNO measurements in the clinic.
In summary this study, using an objective assess-
ment of compliance, indicates that there is
negative but non-significant correlation between
compliance and eNO in unselected asthmatic
patients. The detection of elevated levels of eNO
may be clinically valuable and appears to be
associated with poor regimen compliance in the
majority of subjects but confounding factors such
as poor inhalation technique, hay fever or inter-
current exacerbation must be taken into account
when interpreting such findings. Further work is
required to clarify the role of eNO measurement in
clinical practice.Acknowledgements
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